Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) have received a consensus recommendation of “Moderate Buy” from the eight analysts that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $13.70.

A number of analysts recently issued reports on the company. B. Riley Financial reissued a “buy” rating and issued a $12.00 target price (down from $17.00) on shares of Vanda Pharmaceuticals in a research report on Monday, August 10th. HC Wainwright cut their price target on Vanda Pharmaceuticals from $21.00 to $20.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Friday, July 17th.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Several institutional investors have recently bought and sold shares of VNDA. Quantbot Technologies LP acquired a new position in Vanda Pharmaceuticals during the 2nd quarter worth approximately $29,000. Russell Investments Group Ltd. increased its holdings in Vanda Pharmaceuticals by 456.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 5,328 shares in the last quarter. Legal & General Group Plc acquired a new position in shares of Vanda Pharmaceuticals during the 2nd quarter worth approximately $34,000. Allworth Financial LP acquired a new position in shares of Vanda Pharmaceuticals in the second quarter worth $43,000. Finally, Quarry LP purchased a new stake in Vanda Pharmaceuticals during the 3rd quarter worth about $53,000. 88.14% of the stock is owned by institutional investors and hedge funds.

Vanda Pharmaceuticals Price Performance

Shares of NASDAQ VNDA opened at $5.09 on Monday. The business has a 50-day moving average of $5.42 and a two-hundred day moving average of $6.40. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.61 and a quick ratio of 1.60. The company has a market capitalization of $307.74 million, a price-to-earnings ratio of -1.10 and a beta of 0.64. Vanda Pharmaceuticals has a 1 year low of $4.27 and a 1 year high of $9.94.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.46). The company had revenue of $50.53 million during the quarter, compared to analysts’ expectations of $61.92 million. Vanda Pharmaceuticals had a negative net margin of 127.41% and a negative return on equity of 49.81%. On average, analysts forecast that Vanda Pharmaceuticals will post -3 earnings per share for the current fiscal year.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.